Aurora Cannabis Inc.

ACB Healthcare Drug Manufacturers Specialty & Generic

Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.

3.99 0.11 −2.68%
Market cap
$265.8M
P/E
0.0×
Fwd P/E
−783×
Dividend yield
—
F-score
4/9
Altman Z
−12.34
Beneish M
−2.53
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.82 0.80 0.90 1.28
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(53.59) (733.60) 19.22 (11.49)
P/B ratio
0.45 0.50 0.59 0.82
EV/Sales
0.58 0.53 0.74 1.15
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(3.35) (4.89) (9.25) (25.01)
Current Ratio
5.36 5.94 3.06 3.41
Net Debt/EBITDA
34.68 13.80 (9.14) 4.15
Debt/Equity
0.03 0.04 0.17 0.17
Earnings Yield
(50.54%) (47.71%) (25.59%) (11.58%)
Free Cash Flow Yield
(20.98%) (13.64%) (8.89%) (3.59%)
Free Cash Flow per Share
(0.12) (0.08) 0.15 (0.59)
Book value per Share
6.17 6.53 7.18 7.29
Free Cash Flow
(7.12) (4.28) 8.67 (33.37)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates